Core Viewpoint - COEPTIS, Inc. has announced a strategic partnership with MarketLeverage to enhance affiliate marketing through AI technology integration, aiming to improve marketing efficiency and performance-based strategies [1][2][3]. Company Overview - COEPTIS, Inc. is a biopharmaceutical and technology company focused on innovative biotechnology solutions, including cell therapy platforms for various diseases [7][8]. - The company has established a Technology Division that includes AI-powered marketing software and robotic process automation tools to optimize business processes [9]. Partnership Details - The collaboration between COEPTIS' NexGenAI Affiliates Network and MarketLeverage will leverage advanced automation and data-driven insights to empower affiliates, brands, and marketers [2][4]. - MarketLeverage has a vast network, currently working with 5,500 advertisers and 55,000 publishers, which will enhance the reach and effectiveness of the partnership [2][10]. Market Insights - The artificial intelligence in marketing market is projected to grow from $27.83 billion in 2024 to $35.54 billion in 2025, with a compound annual growth rate (CAGR) of 27.7% [5]. - The market is expected to reach $106.54 billion by 2029, with a CAGR of 31.6%, indicating significant growth potential in the AI-driven marketing sector [5]. Technological Advancements - NexGenAI Affiliates Network provides AI-driven tools for campaign management, predictive analytics, and automated outreach, enhancing the capabilities of affiliates and advertisers [4][11]. - The partnership aims to create a new frontier in performance marketing by combining MarketLeverage's extensive network with NexGenAI's automated tools [3][4].

Core Insights - COEPTIS, Inc. has announced a partnership with MarketLeverage to integrate AI technology into affiliate marketing, aiming to enhance performance-based strategies [1][2][3] - The collaboration will leverage MarketLeverage's extensive network of 5,500 advertisers and 55,000 publishers to drive traffic and improve marketing efficiency [2][3] - The partnership is expected to transform digital marketing by providing affiliates and brands with advanced automation and data-driven insights [3][4] Company Overview - COEPTIS, Inc. is a biopharmaceutical and technology company focused on innovative cell therapy platforms and advanced technologies [7][9] - The company has established a Technology Division that includes AI-powered marketing software and robotic process automation tools [9] - COEPTIS aims to improve patient outcomes through cutting-edge research and development efforts in the biopharmaceutical sector [7][8] Market Trends - The artificial intelligence in marketing market is projected to grow from $27.83 billion in 2024 to $35.54 billion in 2025, reflecting a compound annual growth rate (CAGR) of 27.7% [5] - By 2029, the market size is expected to reach $106.54 billion, with a CAGR of 31.6%, indicating significant growth potential in the AI-driven marketing sector [5]

Core Perspective - COEPTIS, Inc. has launched COEP Venture Group, an investment arm focused on funding and accelerating technology startups in AI, Robotic Process Automation (RPA), and AI Agents [1][2][3] Investment Strategy - COEP Venture Group aims to identify and support high-potential startups that are shaping the future of automation and intelligent systems by providing capital, mentorship, and access to industry networks [2][3] - The investment focus includes advanced machine learning models, AI-driven enterprise solutions, RPA, AI agents, and other emerging technologies such as blockchain and data analytics [8] Leadership and Expertise - Michael Woloshin, a seasoned entrepreneur with extensive experience in technology and marketing automation, will lead COEP Venture Group, leveraging his background to foster innovation and expand market opportunities for emerging tech companies [5] Strategic Initiatives - COEP Venture Group will utilize NexGenAI Solutions Group to provide marketing services to its portfolio companies, ensuring they receive not only funding but also strategic exposure and market positioning [4]

Core Insights - COEPTIS, Inc. successfully closed an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million, indicating strong investor confidence in the company's innovative therapeutic solutions and technology-driven growth [1][2][3] Financing Details - The financing round was led by CJC Investment Trust, controlled by board member Christopher Calise, who increased their initial investment [2] - The Series A Preferred shares are convertible into common stock at a price of $8.00 per share, with investors receiving a 15% equity interest in newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc. [2] Use of Proceeds - The funds will be used to strengthen the company's balance sheet, repay obligations, and support general corporate purposes, alongside enhancing operational capabilities through AI-driven tools from the NexGenAI Affiliates Network platform [3][4] - The additional capital will accelerate the integration of advanced AI solutions and automation capabilities, improving research processes and overall operational efficiency [3] Company Strategy - COEPTIS aims to drive innovation in technology and AI while fostering a culture of responsible innovation to create a self-sustaining business model for long-term success and profitability [4] - The company is focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, with a therapeutic portfolio that includes assets licensed from Deverra Therapeutics [5][6] Technology Division - A newly established Technology Division will enhance operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools [6]

Core Insights - Coeptis Therapeutics Holdings, Inc. has rebranded to COEPTIS, indicating a strategic shift to expand beyond biopharmaceuticals into technology-driven sectors [1][3] - The establishment of a new Technology Division aims to enhance operational capabilities and maximize shareholder value, highlighted by the acquisition of the NexGenAI Affiliates Network platform [1][6] - The integration of NexGenAI's tools will empower COEPTIS to address marketing challenges with AI-driven precision and efficiency, focusing on automation and workflow optimization [2][6] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company dedicated to developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4][5] - The company's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and clinical-stage NK cell therapy technology [5] - COEPTIS is committed to advancing treatment paradigms and improving patient outcomes through cutting-edge research and development efforts [4][5] Technology Division - The newly established Technology Division focuses on enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation [6] - This division aims to optimize business processes and improve overall efficiency, positioning COEPTIS as a self-sustaining entity for long-term growth and profitability [3][6]

Core Insights - Coeptis Therapeutics is expanding its technological initiatives by integrating artificial intelligence and blockchain solutions to enhance operational efficiency and strategic growth [1][2][3] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4][5] - The company operates through subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. [4] Technological Advancements - The successful launch of the Technology Division has introduced transformative AI capabilities, significantly improving operational efficiency and customer engagement [2][6] - The Technology Division includes AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [6] Strategic Vision - The integration of blockchain technology into the Technology Division reflects Coeptis's commitment to adapting to emerging trends and leveraging new market opportunities for enhanced value creation [3] - The company aims to remain at the forefront of technological developments while exploring synergies that benefit customers and shareholders [3]

Core Insights - Coeptis Therapeutics has secured five new clients with a total contract value of $1.7 million, indicating strong market interest in its NexGenAI Affiliates Network platform [1][2] - The company anticipates a revenue stream of $450,000 from Managed Services Agreements valued at $1.25 million, highlighting the immediate market opportunity for its AI-driven marketing solutions [2] - The CEO of Coeptis expressed optimism about the early uptake of the NexGenAI platform, emphasizing its potential to enhance customer engagement and marketing strategies [3][5] Company Overview - Coeptis Therapeutics is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [5] - The company’s product portfolio includes assets licensed from Deverra Therapeutics and a universal CAR T technology licensed from the University of Pittsburgh [5] Technology and Innovation - The NexGenAI Affiliates Network is designed to revolutionize marketing and business operations through AI-driven marketing software, robotic process automation, and data analytics [7] - Upcoming features of the NexGenAI platform include an AI Dialer Service, AI SMS Service, and advanced RPA Assistance, aimed at enhancing communication and operational efficiency [8] Market Trends - The integration of AI in marketing is transforming the industry by enabling businesses to personalize campaigns, optimize in real-time, and gain insights into consumer behavior [4] - As AI technology evolves, it is expected to play a crucial role in shaping various sectors and driving advancements in business practices [4]

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. will implement a 1-for-20 reverse stock split to comply with Nasdaq Capital Market listing requirements, following approval from its board and stockholders [1][4][5] Group 1: Reverse Stock Split Details - The reverse stock split will convert every 20 shares of the Company's common stock into one share, with no fractional shares issued; any resulting fractions will be rounded up to the next whole number [3] - The effective date for the reverse stock split is December 31, 2024, marking the first day of trading on a post-split basis [2][3] Group 2: Purpose and Approval - The reverse stock split aims to help the Company meet the minimum bid price requirement of $1.00 per share as mandated by Nasdaq rules [4] - The reverse split was approved at the Company's Annual Stockholder's Meeting on December 18, 2024, after which the board established the split ratio [5] Group 3: Company Overview - Coeptis Therapeutics is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [7] - The Company’s product portfolio includes assets licensed from Deverra Therapeutics and a universal CAR technology licensed from the University of Pittsburgh [7]

Coeptis Aims to Bring AI Innovation in Biotechnology and TechnologyWEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company specializing in innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, proudly announces the completion of its acquisition of the NexGenAI Affiliates Network platform alongside the official launch of Coeptis Technologies. This new division is strategically aimed a ...

Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers in over 100 countries, Expanding into the Booming Data Security Sector following the upcoming acquisition of NexGenAI Affiliates NetworkWEXFORD, Pa., Dec. 12, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious dis ...